Teva Pharmaceutical Industries Ltd. (TEVA), the world’s largest generic-drug maker, was sued for patent infringement by a U.S. unit of UCB SA (UCB) in a bid to block plans to copy the epilepsy drug Vimpat
Plaintiffs UCB Pharma actions relates to Teva has infringed one or more claims of the Reissued Patent No. RE 38,551 (“the ‘551 patent”) by filing the ANDA No. 204999 seeking approval for the commercial manufacture, use, offer for sale, sale and/or import of Teva USA’s ANDA Products before the expiration of the ’551 patent
Complaint for Patent Infringement:
Civil Action No: 13-cv-01148
Filed on june 28, 2013 in the U.S. District Court for the District of Delaware
Patents in suit:
Plaintiffs UCB Pharma actions relates to Teva has infringed one or more claims of the Reissued Patent No. RE 38,551 (“the ‘551 patent”) by filing the ANDA No. 204999 seeking approval for the commercial manufacture, use, offer for sale, sale and/or import of Teva USA’s ANDA Products before the expiration of the ’551 patent
Complaint for Patent Infringement:
Civil Action No: 13-cv-01148
Filed on june 28, 2013 in the U.S. District Court for the District of Delaware
Patents in suit:
- RE 38,551: “Anticonvulsant enantiomeric amino acid derivatives” by Kohn. Prosecuted by Scully, Scott, Murphy & Presser. Includes 13 claims (1 indep.). Was application 08/818,688. Granted 6/30/1998